Developer docs
API playgroundTry for free, no card

Search company profiles

Arvinas

Full company profile

uuid0000ijm

Namestring
Arvinas
Legal namestring
Arvinas Operations, Inc.
Websiteurl
arvinas.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Arvinas is a clinical-stage biotechnology company headquartered in New Haven, Connecticut, founded in 2013 to commercialize targeted protein degradation therapeutics based on research by Dr. Craig Crews at Yale University. The company's core technology is its proprietary PROTAC (PROteolysis TArgeting Chimeras) Discovery Engine, which designs heterobifunctional small-molecule degraders that harness the body's ubiquitin-proteasome system to selectively eliminate disease-causing proteins - including the ~80% of the proteome considered 'undruggable' by traditional small-molecule inhibitors. The platform incorporates an E3 KnowledgeBase covering more than 600 E3 ligases, DNA-Encoded Library screening, and proprietary linker chemistry (ANGLE), and has produced orally bioavailable candidates capable of penetrating the blood-brain barrier.

The product portfolio spans oncology and neurology. On May 1, 2026, the FDA approved VEPPANU (vepdegestrant) for ER+/HER2-/ESR1-mutated advanced breast cancer - the first-ever approved PROTAC protein degrader - alongside a companion diagnostic (Guardant360 CDx). Clinical-stage assets include ARV-102 (LRRK2 for Parkinson's disease and PSP), ARV-027 (polyQ-AR for SBMA), ARV-393 (BCL6 for non-Hodgkin lymphoma), ARV-806 (KRAS G12D for solid tumors), ARV-6723 (HPK1 for immuno-oncology), and luxdegalutamide (ARV-766) for prostate cancer.

Arvinas monetizes primarily through licensing and collaboration rather than direct commercialization. Revenue streams include upfront payments, development/regulatory/commercial milestones, and tiered royalties on net sales of partner-led products. Major deals include a $150M upfront plus up to $1.01B milestones from Novartis for luxdegalutamide (April 2024), and a $70M upfront plus up to $320M milestones from Rigel for VEPPANU (May 2026), with Rigel handling global commercialization and targeting an August 2026 launch. FY2025 revenue was $262.6M and Q1 2026 revenue was $15.6M; cash and marketable securities of $614.9M (Q1 2026) are stated to fund operations into the second half of 2028.

Short descriptiontext

Arvinas is a clinical-stage biotechnology company that develops PROTAC protein degrader therapeutics using its proprietary targeted protein degradation platform, advancing one FDA-approved breast cancer therapy and multiple clinical-stage oncology and neurology programs, monetized primarily through licensing partnerships with Pfizer, Novartis, and Rigel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, PROTAC therapeutics, oncology drug development, biopharmaceutical research, protein degrader platform
Industry2 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Targeted Protein Degradation Therapeutics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Arvinas generates revenue through upfront payments, development milestones, regulatory milestones, and commercial milestones from licensing agreements with pharmaceutical partners. Examples include $150 million upfront from Novartis for luxdegalutamide and $70 million upfront from Rigel for VEPPANU, plus up to $320 million in potential milestones.

globenewswire.com
2Royalty Income
TypeLicensing Royalties
Description

Arvinas receives tiered royalties on net sales of commercialized products licensed to partners. VEPPANU licensing includes tiered royalties on net sales. Luxdegalutamide licensing includes tiered royalties based upon worldwide net sales.

arvinas.com
3Collaboration Revenue
TypeSubscription Recurring
Description

Revenue from ongoing collaboration activities with pharmaceutical partners including Pfizer for vepdegestrant development. Revenue fluctuates based on development activities and cost sharing arrangements.

globenewswire.com
4Private Placement Financing
TypeLicensing Royalties
Description

Arvinas has raised significant equity capital through private placements. In November 2023, the company secured $350 million through a private placement of common stock and pre-funded warrants to institutional investors including EcoR1 Capital and RTW Investments.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1VEPPANU
Description

FDA-approved PROTAC therapy for ER+/HER2- breast cancer with ESR1 mutations

arvinas.com
+1 more record
Core offering1 text field

Arvinas is a clinical-stage biotechnology company that develops PROTAC (PROteolysis TArgeting Chimera) protein degraders—heterobifunctional small molecules that harness the body's ubiquitin-proteasome system to selectively degrade disease-causing proteins. The company has one FDA-approved product (VEPPANU/vepdegestrant for ER+/HER2-/ESR1-mutated breast cancer) and a pipeline of clinical-stage PROTAC candidates across oncology and neuroscience, which it advances through clinical development and then out-licenses to large pharmaceutical partners for commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • VEPPANU demonstrated 43% reduction in disease progression risk versus fulvestrant in ESR1m population (VERITAC-2 Phase 3 trial)
+2 more records
Product overview1 text field

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapeutics based on its proprietary PROTAC (PROteolysis TArgeting Chimera) platform. The company has one FDA-approved product (VEPPANU for breast cancer), multiple clinical-stage programs (ARV-102 for neurological diseases, ARV-027 for SBMA, ARV-393 for lymphoma, ARV-806 for KRAS G12D cancers, ARV-6723 for solid tumors), and a licensed prostate cancer program (luxdegalutamide). The PROTAC Discovery Engine enables development of degraders that can target previously 'undruggable' proteins by leveraging the cell's natural ubiquitin-proteasome system.

Product and service2 records
1VEPPANU (vepdegestrant)
CategoryApproved Targeted Protein Degradation Therapy
Description

First FDA-approved PROTAC protein degrader therapy, indicated for adults with ER+/HER2-/ESR1-mutated advanced or metastatic breast cancer following disease progression after at least one line of endocrine therapy. Works by selectively degrading the estrogen receptor protein in patients whose cancers are driven by ESR1 mutations. Licensed to Rigel Pharmaceuticals for global development, manufacturing, and commercialization; commercial launch expected August 2026.

2ARV-102 (LRRK2 degrader)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1The Michael J. Fox Foundation
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-06-04
Description

Arvinas joined The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson's Precision Medicine Initiative (PPMI) to support advancement of ARV-102, its investigational PROTAC drug targeting LRRK2 for neurodegenerative diseases. The programs provide Arvinas access to collaborative research infrastructure, preclinical and translational resources, and open-access datasets to inform clinical strategy.

stocktitan.net
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2026-05-04
Description

Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). The blood-based test enables non-invasive identification of patients with ESR1 mutations eligible for the targeted PROTAC therapy. The test is covered by Medicare and commercial payers representing more than 300 million covered lives.

3Rigel Pharmaceuticals
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-01
Description

In May 2026, Arvinas and Pfizer entered into a license agreement with Rigel Pharmaceuticals for the exclusive global development, manufacturing, and commercialization rights for VEPPANU (vepdegestrant). Arvinas and Pfizer received $85 million in upfront and transition payments ($70 million upfront plus $15 million development transition costs) and are eligible to receive up to $320 million in development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales. Rigel expects to commercially launch VEPPANU in August 2026.

arvinas.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-01
Description

In April 2024, Arvinas entered into a global license agreement with Novartis for the development and commercialization of luxdegalutamide (ARV-766, also known as JSB462) for the treatment of prostate cancer. The deal also included the sale of the AR-V7 program to Novartis. Arvinas received a one-time upfront payment of $150 million and is eligible to receive up to $1.01 billion in additional milestone payments plus tiered royalties on worldwide net sales.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

In January 2018, Arvinas announced a research and collaboration license agreement with Pfizer for the discovery and development of drug candidates using Arvinas' PROTAC Discovery Engine. In July 2021, Arvinas and Pfizer expanded collaboration to globally develop and commercialize vepdegestrant. Following FDA approval of VEPPANU in May 2026, the companies licensed commercialization rights to Rigel while retaining sublicensing revenue rights outside the U.S.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-10-01
Description

In October 2015, Arvinas formed a strategic license agreement with Genentech to develop new therapeutics using Arvinas' PROTAC Discovery Engine. The collaboration was expanded in November 2017 to encompass additional disease targets. One target remains under the Genentech agreement.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharma that licensed Arvinas' luxdegalutamide for $150M upfront + up to $1.01B milestones. Comparable as a major oncology-focused pharmaceutical incumbent with internal degrader efforts (e.g., viaを買収 Dunad) and active PROTAC interest.

TypeBroad incumbent
Description

Global pharmaceutical incumbent that is Arvinas' longest-standing strategic partner since 2018 and co-developer of vepdegestrant. Comparable as a broad oncology and protein-degradation-adjacent player, though at vastly larger scale and across many modalities.

TypeDirect peer
Description

Clinical-stage biotech developing heterobifunctional small molecule protein degraders using its Pegasus platform against immunology and oncology targets (IRAK4, STAT6). Directly comparable to Arvinas as a fellow pure-play targeted protein degrader pursuing similar oncology and immunology indications.

4Rigel Pharmaceuticals
TypeRegional player
Description

Commercial-stage US biotech that licensed global rights to VEPPANU from Arvinas/Pfizer. Comparable as a smaller US-based oncology/immunology biotech commercializing an Arvinas-originated PROTAC, illustrating Arvinas' partner-dependent go-to-market model.

TypeDirect peer
Description

Clinical-stage targeted protein degrader company with a broad pipeline (BTK degrader NX-2127, STAT6, etc.) and strategic collaborations with Gilead, Sanofi, and Pfizer. Highly comparable platform and business model to Arvinas, including partnership-driven revenue.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics against chromatin regulatory proteins, including protein degrader approaches. Comparable platform-stage biotech with oncology focus and similar capital intensity profile.

7Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharma with active targeted protein degradation and CELMoD (cereblon-based degrader) programs through its acquired Celgene franchise. Comparable as a major degrader-medicine developer and former employer of several Arvinas executives.

TypeEmerging player
Description

Emerging targeted protein degradation company developing next-generation 'next-generation' TPD molecules with differentiated E3 ligase recruitment. Comparable to Arvinas at the protein degrader platform level though earlier-stage and pre-clinical.

TypeDirect peer
Description

Clinical-stage developer of molecular glue degraders (MGDs) leveraging cereblon- and VHL-based approaches against oncology and immunology targets including GSPT1, NEK7, and BCL11A. Closely comparable to Arvinas' PROTAC protein degradation modality and similar pipeline stage.

TypeDirect peer
Description

Clinical-stage biotech developing small molecule degraders (TORPEDO platform) against oncology targets including BCL6 and IKZF1/3. Direct competitor to Arvinas in protein degrader modality with overlapping oncology pipeline targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arvinas

Targeted Protein Degradation Therapeuticsarvinas.com

Arvinas is a clinical-stage biotechnology company that develops PROTAC protein degrader therapeutics using its proprietary targeted protein degradation platform, advancing one FDA-approved breast cancer therapy and multiple clinical-stage oncology and neurology programs, monetized primarily through licensing partnerships with Pfizer, Novartis, and Rigel.

What Arvinas does

Arvinas is a clinical-stage biotechnology company headquartered in New Haven, Connecticut, founded in 2013 to commercialize targeted protein degradation therapeutics based on research by Dr. Craig Crews at Yale University. The company's core technology is its proprietary PROTAC (PROteolysis TArgeting Chimeras) Discovery Engine, which designs heterobifunctional small-molecule degraders that harness the body's ubiquitin-proteasome system to selectively eliminate disease-causing proteins - including the ~80% of the proteome considered 'undruggable' by traditional small-molecule inhibitors. The platform incorporates an E3 KnowledgeBase covering more than 600 E3 ligases, DNA-Encoded Library screening, and proprietary linker chemistry (ANGLE), and has produced orally bioavailable candidates capable of penetrating the blood-brain barrier.

The product portfolio spans oncology and neurology. On May 1, 2026, the FDA approved VEPPANU (vepdegestrant) for ER+/HER2-/ESR1-mutated advanced breast cancer - the first-ever approved PROTAC protein degrader - alongside a companion diagnostic (Guardant360 CDx). Clinical-stage assets include ARV-102 (LRRK2 for Parkinson's disease and PSP), ARV-027 (polyQ-AR for SBMA), ARV-393 (BCL6 for non-Hodgkin lymphoma), ARV-806 (KRAS G12D for solid tumors), ARV-6723 (HPK1 for immuno-oncology), and luxdegalutamide (ARV-766) for prostate cancer.

Arvinas monetizes primarily through licensing and collaboration rather than direct commercialization. Revenue streams include upfront payments, development/regulatory/commercial milestones, and tiered royalties on net sales of partner-led products. Major deals include a $150M upfront plus up to $1.01B milestones from Novartis for luxdegalutamide (April 2024), and a $70M upfront plus up to $320M milestones from Rigel for VEPPANU (May 2026), with Rigel handling global commercialization and targeting an August 2026 launch. FY2025 revenue was $262.6M and Q1 2026 revenue was $15.6M; cash and marketable securities of $614.9M (Q1 2026) are stated to fund operations into the second half of 2028.

Arvinas firmographics

Firmographics
Name
Arvinas
Legal name
Arvinas Operations, Inc.
Website
https://arvinas.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
251–500 employees
Short description
Arvinas is a clinical-stage biotechnology company that develops PROTAC protein degrader therapeutics using its proprietary targeted protein degradation platform, advancing one FDA-approved breast cancer therapy and multiple clinical-stage oncology and neurology programs, monetized primarily through licensing partnerships with Pfizer, Novartis, and Rigel.
Ownership category
akta.pro rank

Arvinas industry classification

Industry
Product category
Targeted Protein Degradation Therapeutics
NAICS
Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Targeted protein degradation
  • PROTAC therapeutics
  • Oncology drug development
  • Biopharmaceutical research
  • Protein degrader platform

Where Arvinas is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Arvinas business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing and Milestone Payments: Arvinas generates revenue through upfront payments, development milestones, regulatory milestones, and commercial milestones from licensing agreements with pharmaceutical partners. Examples include $150 million upfront from Novartis for luxdegalutamide and $70 million upfront from Rigel for VEPPANU, plus up to $320 million in potential milestones.
  2. Royalty Income: Arvinas receives tiered royalties on net sales of commercialized products licensed to partners. VEPPANU licensing includes tiered royalties on net sales. Luxdegalutamide licensing includes tiered royalties based upon worldwide net sales.
  3. Collaboration Revenue: Revenue from ongoing collaboration activities with pharmaceutical partners including Pfizer for vepdegestrant development. Revenue fluctuates based on development activities and cost sharing arrangements.
  4. Private Placement Financing: Arvinas has raised significant equity capital through private placements. In November 2023, the company secured $350 million through a private placement of common stock and pre-funded warrants to institutional investors including EcoR1 Capital and RTW Investments.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Arvinas product offering

Product offering

Core offering

Arvinas is a clinical-stage biotechnology company that develops PROTAC (PROteolysis TArgeting Chimera) protein degraders—heterobifunctional small molecules that harness the body's ubiquitin-proteasome system to selectively degrade disease-causing proteins. The company has one FDA-approved product (VEPPANU/vepdegestrant for ER+/HER2-/ESR1-mutated breast cancer) and a pipeline of clinical-stage PROTAC candidates across oncology and neuroscience, which it advances through clinical development and then out-licenses to large pharmaceutical partners for commercialization.

Product overview

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapeutics based on its proprietary PROTAC (PROteolysis TArgeting Chimera) platform. The company has one FDA-approved product (VEPPANU for breast cancer), multiple clinical-stage programs (ARV-102 for neurological diseases, ARV-027 for SBMA, ARV-393 for lymphoma, ARV-806 for KRAS G12D cancers, ARV-6723 for solid tumors), and a licensed prostate cancer program (luxdegalutamide). The PROTAC Discovery Engine enables development of degraders that can target previously 'undruggable' proteins by leveraging the cell's natural ubiquitin-proteasome system.

Differentiator

Problem solved

Functional benefit

Brands

  • VEPPANU: FDA-approved PROTAC therapy for ER+/HER2- breast cancer with ESR1 mutations
  • PROTAC Discovery Engine

Products and services

  • VEPPANU (vepdegestrant) First FDA-approved PROTAC protein degrader therapy, indicated for adults with ER+/HER2-/ESR1-mutated advanced or metastatic breast cancer following disease progression after at least one line of endocrine therapy. Works by selectively degrading the estrogen receptor protein in patients whose cancers are driven by ESR1 mutations. Licensed to Rigel Pharmaceuticals for global development, manufacturing, and commercialization; commercial launch expected August 2026.
  • ARV-102 (LRRK2 degrader)

Quantifiable outcome

  • VEPPANU demonstrated 43% reduction in disease progression risk versus fulvestrant in ESR1m population (VERITAC-2 Phase 3 trial)
  • +2 more outcomes

Companies that use Arvinas

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Arvinas technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Arvinas partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered supporting, core and minor.

  • The Michael J. Fox FoundationsupportingStrategic or Co-development Partner · 4 June 2026Arvinas joined The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson's Precision Medicine Initiative (PPMI) to support advancement of ARV-102, its investigational PROTAC drug targeting LRRK2 for neurodegenerative diseases. The programs provide Arvinas access to collaborative research infrastructure, preclinical and translational resources, and open-access datasets to inform clinical strategy.
  • Guardant HealthsupportingTechnology or Integration · 4 May 2026Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). The blood-based test enables non-invasive identification of patients with ESR1 mutations eligible for the targeted PROTAC therapy. The test is covered by Medicare and commercial payers representing more than 300 million covered lives.
  • Rigel PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 May 2026In May 2026, Arvinas and Pfizer entered into a license agreement with Rigel Pharmaceuticals for the exclusive global development, manufacturing, and commercialization rights for VEPPANU (vepdegestrant). Arvinas and Pfizer received $85 million in upfront and transition payments ($70 million upfront plus $15 million development transition costs) and are eligible to receive up to $320 million in development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales. Rigel expects to commercially launch VEPPANU in August 2026.
  • Novartis AGcoreChannel Partner/ Reseller/ Distributor · 1 April 2024In April 2024, Arvinas entered into a global license agreement with Novartis for the development and commercialization of luxdegalutamide (ARV-766, also known as JSB462) for the treatment of prostate cancer. The deal also included the sale of the AR-V7 program to Novartis. Arvinas received a one-time upfront payment of $150 million and is eligible to receive up to $1.01 billion in additional milestone payments plus tiered royalties on worldwide net sales.
  • Pfizer Inc.coreStrategic or Co-development Partner · 1 January 2018In January 2018, Arvinas announced a research and collaboration license agreement with Pfizer for the discovery and development of drug candidates using Arvinas' PROTAC Discovery Engine. In July 2021, Arvinas and Pfizer expanded collaboration to globally develop and commercialize vepdegestrant. Following FDA approval of VEPPANU in May 2026, the companies licensed commercialization rights to Rigel while retaining sublicensing revenue rights outside the U.S.
  • Genentech (Roche Group)minorStrategic or Co-development Partner · 1 October 2015In October 2015, Arvinas formed a strategic license agreement with Genentech to develop new therapeutics using Arvinas' PROTAC Discovery Engine. The collaboration was expanded in November 2017 to encompass additional disease targets. One target remains under the Genentech agreement.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Arvinas competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Global pharma that licensed Arvinas' luxdegalutamide for $150M upfront + up to $1.01B milestones. Comparable as a major oncology-focused pharmaceutical incumbent with internal degrader efforts (e.g., viaを買収 Dunad) and active PROTAC interest.
  • Pfizer: Global pharmaceutical incumbent that is Arvinas' longest-standing strategic partner since 2018 and co-developer of vepdegestrant. Comparable as a broad oncology and protein-degradation-adjacent player, though at vastly larger scale and across many modalities.
  • Bristol Myers Squibb: Large pharma with active targeted protein degradation and CELMoD (cereblon-based degrader) programs through its acquired Celgene franchise. Comparable as a major degrader-medicine developer and former employer of several Arvinas executives.

Direct peers

  • Kymera Therapeutics: Clinical-stage biotech developing heterobifunctional small molecule protein degraders using its Pegasus platform against immunology and oncology targets (IRAK4, STAT6). Directly comparable to Arvinas as a fellow pure-play targeted protein degrader pursuing similar oncology and immunology indications.
  • Nurix Therapeutics: Clinical-stage targeted protein degrader company with a broad pipeline (BTK degrader NX-2127, STAT6, etc.) and strategic collaborations with Gilead, Sanofi, and Pfizer. Highly comparable platform and business model to Arvinas, including partnership-driven revenue.
  • Foghorn Therapeutics: Clinical-stage biotech developing therapeutics against chromatin regulatory proteins, including protein degrader approaches. Comparable platform-stage biotech with oncology focus and similar capital intensity profile.
  • Monte Rosa Therapeutics: Clinical-stage developer of molecular glue degraders (MGDs) leveraging cereblon- and VHL-based approaches against oncology and immunology targets including GSPT1, NEK7, and BCL11A. Closely comparable to Arvinas' PROTAC protein degradation modality and similar pipeline stage.
  • C4 Therapeutics: Clinical-stage biotech developing small molecule degraders (TORPEDO platform) against oncology targets including BCL6 and IKZF1/3. Direct competitor to Arvinas in protein degrader modality with overlapping oncology pipeline targets.

Regional players

  • Rigel Pharmaceuticals: Commercial-stage US biotech that licensed global rights to VEPPANU from Arvinas/Pfizer. Comparable as a smaller US-based oncology/immunology biotech commercializing an Arvinas-originated PROTAC, illustrating Arvinas' partner-dependent go-to-market model.

Emerging players

  • Amphista Therapeutics: Emerging targeted protein degradation company developing next-generation 'next-generation' TPD molecules with differentiated E3 ligase recruitment. Comparable to Arvinas at the protein degrader platform level though earlier-stage and pre-clinical.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

Arvinas social profiles

Digital presence

Arvinas financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arvinas leadership team

Management profile

Number of profiles

Profiles18 records

Arvinas funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arvinas M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arvinas

What does Arvinas do?

Arvinas is a clinical-stage biotechnology company that develops PROTAC (PROteolysis TArgeting Chimera) protein degraders—heterobifunctional small molecules that harness the body's ubiquitin-proteasome system to selectively degrade disease-causing proteins. The company has one FDA-approved product (VEPPANU/vepdegestrant for ER+/HER2-/ESR1-mutated breast cancer) and a pipeline of clinical-stage PROTAC candidates across oncology and neuroscience, which it advances through clinical development and then out-licenses to large pharmaceutical partners for commercialization.

Is Arvinas a public or private company?

Arvinas is a public company. It is classified as public and is currently operating.

When was Arvinas founded?

Arvinas was founded in 2013. It employs 251 to 500 people.

Where is Arvinas based?

Arvinas is headquartered in New Haven, United States, in the North America region.

How does Arvinas make money?

Four revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are royalty Income, collaboration Revenue and private Placement Financing.

Who are Arvinas's main competitors?

Broad incumbents on record are Novartis, Pfizer and Bristol Myers Squibb. Direct peers are Kymera Therapeutics, Nurix Therapeutics, Foghorn Therapeutics, Monte Rosa Therapeutics and C4 Therapeutics. Rigel Pharmaceuticals is listed as a regional player. Amphista Therapeutics is listed as an emerging player.

Does Arvinas have an API?

No public API is recorded for Arvinas.

What industry is Arvinas in?

Arvinas's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAK, Therapeutic Enzymes & Enzyme Replacement Therapies (ERT). Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooExperimental Drug That Destroys Testosterone Receptors Shows Promise Against Prostate CancerAn experimental drug, bavdegalutamide, that degrades testosterone receptors showed promise in a phase I/II trial for advanced prostate cancer. Among patients with T878/H875 mutations, 60% saw prostate-specific antigen drop by at least half, while only 3-4% of others did. Arvinas is now prioritizing a similar drug with fewer side effects.Business & FinancialArvinas To Present At Jefferies Global Healthcare ConferenceArvinas will present at the Jefferies Global Healthcare Conference, with a live audio webcast available on its website. The company's PROTAC platform includes ARV-393 for non-Hodgkin lymphoma, ARV-102 for neurodegenerative disorders, and ARV-6723 for solid tumors, with ARV-806 in clinical trials.Stock TitanArvinas joins Jefferies healthcare conference Nov. 18Arvinas management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company, a clinical-stage biotechnology firm, will present its PROTAC protein degrader platform and multiple investigational drugs, including ARV-393 and ARV-102.Seeking AlphaArvinas, Inc. (ARVN) Q3 2026 Earnings Call TranscriptArvinas held its Q3 2026 earnings call on November 3, 2026, with CEO Randy Teel, CFO Andrew Saik, and CSCO Angela Cacace. The company issued a press release with financial results, and the call included forward-looking statements with associated risks.MarketScreenerArvinas, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Arvinas reported Q3 2026 sales of $0.5 million and a net loss of $53.9 million, both worse than the prior year. For the nine months, sales were $265.8 million and net income was $57.9 million, reversing a prior-year loss. The company is developing PROTAC drugs, including vepdegestrant with Pfizer.Quiver QuantitativeARVINAS ($ARVN) Releases Q3 2026 Earnings | ARVN Stock NewsARVINAS reported Q3 2026 earnings of -$0.82 per share, beating estimates of -$0.89, but revenue of $500,000 missed estimates of $22.94 million. Insiders sold 8 times in the past six months, and hedge fund activity shows mixed institutional moves.Stock TitanArvinas brings back $25,000 early-career research awardArvinas announced the return of its Early Career Researcher Award, offering $25,000 to recognize research in targeted protein degradation. Nominations open November 1, 2026, and close December 31, 2026, with the winner recognized in mid-2027.Business & FinancialArvinas To Report Third Quarter 2026 Financial Results On November 3, 2026Arvinas will report its third-quarter 2026 financial results on November 3, 2026, with a webcast available on its investor page. The company, a clinical-stage biotech, is developing PROTAC protein degraders, including ARV-393 for lymphoma and ARV-102 for neurodegenerative disorders.Ticker ReportReviewing uniQure (NASDAQ:QURE) & Arvinas (NASDAQ:ARVN)Arvinas and uniQure are compared on institutional ownership, profitability, and analyst ratings. Arvinas beats uniQure on 10 of 14 factors, with higher revenue and earnings, while uniQure has a stronger consensus rating and higher upside. Analysts favor uniQure despite Arvinas's better financials.Business Model AnalystThis Breast Cancer Pill Made FDA History. It Fits 1% of Patients.The FDA approved Veppanu, the first designed protein degrader, on May 1, 2026, for ESR1-mutated breast cancer. Arvinas and Pfizer sold global rights to Rigel for $70 million upfront, with up to $320 million in milestones. The drug targets about 1% of new breast cancer patients.